Total | AR | AR not done | ||||||
---|---|---|---|---|---|---|---|---|
N (71) | % | N (38) | % | N (33) | % | P -value | ||
Age (Ys) | <50 | 37 | 52.1% | 22 | 57.9% | 15 | 45.5% | 0.2 |
≥50 | 34 | 47.9% | 16 | 42.1% | 18 | 54.5% | ||
Sex | Male | 47 | 66.2% | 24 | 63.2% | 23 | 69.7% | 0.4 |
female | 24 | 33.8% | 14 | 36.8% | 10 | 30.3% | ||
Tumor size | Small (<3 cm) | 23 | 32.4% | 9 | 23.7% | 14 | 42.4% | 0.07 |
Large (≥3 cm) | 48 | 67.6% | 29 | 76.3% | 19 | 57.6% | ||
Stage | T 2a | 11 | 15.5% | 7 | 18.4% | 4 | 12.1% | 0.5 |
T 2b | 50 | 70.4% | 27 | 71.1% | 23 | 69.7% | ||
T 3 | 7 | 9.9% | 2 | 5.3% | 5 | 15.2% | ||
T 4a | 3 | 4.2% | 2 | 5.3% | 1 | 3.0% | ||
Grade | 1 | 25 | 35.2% | 16 | 42.1% | 9 | 27.3% | 0.09 |
2 | 32 | 45.1% | 18 | 47.4% | 14 | 42.4% | ||
3 | 14 | 19.7% | 4 | 10.5% | 10 | 30.3% | ||
LN | +ve | 10 | 14.1% | 3 | 7.9% | 7 | 21.2% | 0.3 |
-ve | 39 | 54.9% | 23 | 60.5% | 16 | 48.5% | ||
Missing data | 22 | 31.0% | 12 | 31.6% | 10 | 30.3% | ||
Bcl-XL | -ve | 42 | 59.2% | 23 | 60.5% | 19 | 57.6% | 0.5 |
+ve | 29 | 40.8% | 15 | 39.5% | 14 | 42.4% |